Part F | 29
726 Part F Marine Derived Metabolites
29.37
J.M. Absalon, F.O. Smith: Treatment strategies for
pediatric acute myeloidleukemia, Expert Opin,
Pharmacother. 10(1), 57–79 (2009)
29.38
MARTINDALE: The Complete Drug Reference
(database on the internet). Cytarabine. Thomson MICROMEDEX (2009). Available at: www.
micromedex.com. Accessed December 1, 2009.
Micromedex Health Care, Martindale - The
Complete Drug Reference (www.micromedex.
com)
29.39
MARTINDALE: The Complete Drug Reference
(database on the internet). Vidarabine. Thomson MICROMEDEX (2009). Available at: www.
micromedex.com. Accessed December 1, 2009.
Micromedex Health Care, Martindale - The
Complete Drug Reference (www.micromedex.
com)
29.40
K.L. Rinehart, A.M. Lithgow-Bertelloni: Dehydrodidemnin B, World Patent Ser. WO910 4985 A1
(1991)
29.41
E. Erba, M. Serafini, G. Gaipa, G. Tognon, S. Marchini, N. Celli, D. Rotilio, M. Broggini, J. Jimeno,
G.T. Faircloth, A. Biondi, M. D’Incalci: Effect of Aplidin in acute lymphoblastic leukaemia cells. Br.
J, Cancer 89(4), 763–773 (2003)
29.42
C.S. Mitsiades, E.M. Ocio, A. Pandiella, P. Maiso,
C. Gajate, M. Garayoa, D. Vilanova, J.C. Montero, N. Mitsiades, C.J. McMullan, N.C. Munshi,
T. Hideshima, D. Chauhan, P. Aviles, G. Otero,
G. Faircloth, M.V. Mateos, P.G. Richardson,
F. Mollinedo, J.F. San-Miguel, K.C. Anderson:
Aplidin, a marine organism–derived compound
with potent antimyeloma activity in vitro and in
vivo, Cancer Res. 68, 5216 (2008)
29.43
M. Broggini, S.V. Marchini, E. Galliera, P. Borsotti, G. Taraboletti, E. Erba, M. Sironi, J. Jimeno,
G.T. Faircloth, R. Giavazzi, M. D’Incalci: Aplidine,
a new anticancer agent of marine origin, inhibits
vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine
loop in human leukemia cells MOLT-4, Leukemia
17(1), 52–59 (2003)
29.44
A. Cuadrado, L. González, Y. Suárez, T. Martinez, A. Munoz: JNK activation is critical for
Aplidin-induced apoptosis, Oncogene 27, 4673–
4680 (2004)
29.45
Y. Hirata, D. Uemura: Halichondrins-antitumor
polyether macrolides from a marine sponge, Pure
Appl. Chem. 58, 701–710 (1986)
29.46
D. Uemura, K. Takahashi, T. Yamamoto,
C. Katayama, J. Tanaka, Y. Okumura, Y. Hirata: Norhalichondrin A: An antitumor polyether
macrolide from a marine sponge, J. Am. Chem.
Soc. 107, 4796–4798 (1985)
29.47
A. McBride, S.K. Butler: Eribulinmesylate: A novel
halichondrin B analogue for the treatment of
metastatic breast cancer, Am. J. Health Syst.
Pharm. 69, 745–755 (2012)
29.48
T. Okouneva, O. Azarenko, L. Wilson, B.A. Littlefield, M.A. Jordan: Inhibition of centromere
dynamics by eribulin (E7389) during mitotic
metaphase, Mol. Cancer Ther. 7, 2003–2011 (2008)
29.49
G. Kuznetsov, M.J. Towle, H. Cheng, T. Kawamura,
K. TenDyke, D. Liu, Y. Kishi, M.J. Yu, B.A. Littlefield: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog
E7389, Cancer Res. 64, 5760–5766 (2004)
29.50
M.J. Yu, B.A. Littlefield, Y. Kishi: Discovery of
E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. In: Anticancer Agents
from Natural Products, ed. by G.M. Cragg,
D.G.I. Kingston, D.J. Newman (CRC, Taylor and
Francis Group, Boca Raton, Fl 2005) pp. 241–
265
29.51
J.B. Forero, M.K. Heiskala, N. Meneses, K. Chandrawansa, F. Fang, G. Shapiro, S.Z. Fields, S. Silberman, L. Vahdat: E7389, a novel anti-tubulin,
in patients with refractory breast cancer, J. Clin.
Oncol. 24(18), 653 (2006)
29.52
M.A. Becerro, G. Goetz, V.J. Paul, P.J. Scheuer:
Chemical defenses of the sacoglossan mollusk
Elysia rufescens and its host alga Bryopsis sp,
J. Chem. Ecol. 27, 2287–2299 (2001)
29.53
M. Garcia-Rocha, P. Bonay, J. Avila: The antitumoral compound Kahalalide F acts on celllysosomes, Cancer Lett. 99, 43–50 (1996)
29.54
Y. Suarez, L. González, A. Cuadrado, M. Berciano,
M. Lafarga, A. Muñoz: Kahalalide F, a new
marine-derived compound, induces oncosis in
human prostate and breast cancer cells, Mol.
Cancer Ther. 2, 863–872 (2003)
29.55
M.L. Janmaat, J.A. Rodriguez, J. Jimeno,
F.A.E. Kruyt, G. Giaccone: Kahalalide F induces
necrosis-like cell death that involves depletion
of ErbB3 and inhibition of Akt signaling, Mol.
Pharmacol. 68, 502–510 (2005)
29.56
M.T. Hamann, P.J. Scheuer: F. Kahalalide: A bioactive depsipeptide from the Sacoglossan mollusk
Elysia rufescens and the green alga Bryopsis sp,
J. Am. Chem. Soc. 115, 5825–5826 (1993)
29.57
C. Ciruelos, J.M. Trigo, B. Pardo, L. Paz-Ares,
N. Estaun, C. Cuadra, M.J. Dominguez, A. Marin,
A. Ruiz, J. Jimeno, M.A. Izquierdo: A phase I
clinical and pharmacokinetic (PK) study with Kahalalide F (KF) in patients (pts) with advanced
solid tumors (AST) with a continuous weekly (W)
1-hour iv infusion schedule, Eur. J. Cancer 38, S33
(2002)
29.58
G.R. Pettit: Progress in the discovery of biosynthetic anticancer drugs, J. Nat. Prod. 59, 812–821
(1996)
29.59
G.R. Pettit, C.L. Herald, D.L. Doubek, D.L. Herald, E. Arnold, J. Clardy: Isolation and structure of
bryostatin-1, J. Am. Chem. Soc. 104, 6846–6848
(1982)
726 Part F Marine Derived Metabolites
29.37
J.M. Absalon, F.O. Smith: Treatment strategies for
pediatric acute myeloidleukemia, Expert Opin,
Pharmacother. 10(1), 57–79 (2009)
29.38
MARTINDALE: The Complete Drug Reference
(database on the internet). Cytarabine. Thomson MICROMEDEX (2009). Available at: www.
micromedex.com. Accessed December 1, 2009.
Micromedex Health Care, Martindale - The
Complete Drug Reference (www.micromedex.
com)
29.39
MARTINDALE: The Complete Drug Reference
(database on the internet). Vidarabine. Thomson MICROMEDEX (2009). Available at: www.
micromedex.com. Accessed December 1, 2009.
Micromedex Health Care, Martindale - The
Complete Drug Reference (www.micromedex.
com)
29.40
K.L. Rinehart, A.M. Lithgow-Bertelloni: Dehydrodidemnin B, World Patent Ser. WO910 4985 A1
(1991)
29.41
E. Erba, M. Serafini, G. Gaipa, G. Tognon, S. Marchini, N. Celli, D. Rotilio, M. Broggini, J. Jimeno,
G.T. Faircloth, A. Biondi, M. D’Incalci: Effect of Aplidin in acute lymphoblastic leukaemia cells. Br.
J, Cancer 89(4), 763–773 (2003)
29.42
C.S. Mitsiades, E.M. Ocio, A. Pandiella, P. Maiso,
C. Gajate, M. Garayoa, D. Vilanova, J.C. Montero, N. Mitsiades, C.J. McMullan, N.C. Munshi,
T. Hideshima, D. Chauhan, P. Aviles, G. Otero,
G. Faircloth, M.V. Mateos, P.G. Richardson,
F. Mollinedo, J.F. San-Miguel, K.C. Anderson:
Aplidin, a marine organism–derived compound
with potent antimyeloma activity in vitro and in
vivo, Cancer Res. 68, 5216 (2008)
29.43
M. Broggini, S.V. Marchini, E. Galliera, P. Borsotti, G. Taraboletti, E. Erba, M. Sironi, J. Jimeno,
G.T. Faircloth, R. Giavazzi, M. D’Incalci: Aplidine,
a new anticancer agent of marine origin, inhibits
vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine
loop in human leukemia cells MOLT-4, Leukemia
17(1), 52–59 (2003)
29.44
A. Cuadrado, L. González, Y. Suárez, T. Martinez, A. Munoz: JNK activation is critical for
Aplidin-induced apoptosis, Oncogene 27, 4673–
4680 (2004)
29.45
Y. Hirata, D. Uemura: Halichondrins-antitumor
polyether macrolides from a marine sponge, Pure
Appl. Chem. 58, 701–710 (1986)
29.46
D. Uemura, K. Takahashi, T. Yamamoto,
C. Katayama, J. Tanaka, Y. Okumura, Y. Hirata: Norhalichondrin A: An antitumor polyether
macrolide from a marine sponge, J. Am. Chem.
Soc. 107, 4796–4798 (1985)
29.47
A. McBride, S.K. Butler: Eribulinmesylate: A novel
halichondrin B analogue for the treatment of
metastatic breast cancer, Am. J. Health Syst.
Pharm. 69, 745–755 (2012)
29.48
T. Okouneva, O. Azarenko, L. Wilson, B.A. Littlefield, M.A. Jordan: Inhibition of centromere
dynamics by eribulin (E7389) during mitotic
metaphase, Mol. Cancer Ther. 7, 2003–2011 (2008)
29.49
G. Kuznetsov, M.J. Towle, H. Cheng, T. Kawamura,
K. TenDyke, D. Liu, Y. Kishi, M.J. Yu, B.A. Littlefield: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog
E7389, Cancer Res. 64, 5760–5766 (2004)
29.50
M.J. Yu, B.A. Littlefield, Y. Kishi: Discovery of
E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. In: Anticancer Agents
from Natural Products, ed. by G.M. Cragg,
D.G.I. Kingston, D.J. Newman (CRC, Taylor and
Francis Group, Boca Raton, Fl 2005) pp. 241–
265
29.51
J.B. Forero, M.K. Heiskala, N. Meneses, K. Chandrawansa, F. Fang, G. Shapiro, S.Z. Fields, S. Silberman, L. Vahdat: E7389, a novel anti-tubulin,
in patients with refractory breast cancer, J. Clin.
Oncol. 24(18), 653 (2006)
29.52
M.A. Becerro, G. Goetz, V.J. Paul, P.J. Scheuer:
Chemical defenses of the sacoglossan mollusk
Elysia rufescens and its host alga Bryopsis sp,
J. Chem. Ecol. 27, 2287–2299 (2001)
29.53
M. Garcia-Rocha, P. Bonay, J. Avila: The antitumoral compound Kahalalide F acts on celllysosomes, Cancer Lett. 99, 43–50 (1996)
29.54
Y. Suarez, L. González, A. Cuadrado, M. Berciano,
M. Lafarga, A. Muñoz: Kahalalide F, a new
marine-derived compound, induces oncosis in
human prostate and breast cancer cells, Mol.
Cancer Ther. 2, 863–872 (2003)
29.55
M.L. Janmaat, J.A. Rodriguez, J. Jimeno,
F.A.E. Kruyt, G. Giaccone: Kahalalide F induces
necrosis-like cell death that involves depletion
of ErbB3 and inhibition of Akt signaling, Mol.
Pharmacol. 68, 502–510 (2005)
29.56
M.T. Hamann, P.J. Scheuer: F. Kahalalide: A bioactive depsipeptide from the Sacoglossan mollusk
Elysia rufescens and the green alga Bryopsis sp,
J. Am. Chem. Soc. 115, 5825–5826 (1993)
29.57
C. Ciruelos, J.M. Trigo, B. Pardo, L. Paz-Ares,
N. Estaun, C. Cuadra, M.J. Dominguez, A. Marin,
A. Ruiz, J. Jimeno, M.A. Izquierdo: A phase I
clinical and pharmacokinetic (PK) study with Kahalalide F (KF) in patients (pts) with advanced
solid tumors (AST) with a continuous weekly (W)
1-hour iv infusion schedule, Eur. J. Cancer 38, S33
(2002)
29.58
G.R. Pettit: Progress in the discovery of biosynthetic anticancer drugs, J. Nat. Prod. 59, 812–821
(1996)
29.59
G.R. Pettit, C.L. Herald, D.L. Doubek, D.L. Herald, E. Arnold, J. Clardy: Isolation and structure of
bryostatin-1, J. Am. Chem. Soc. 104, 6846–6848
(1982)